Published in Acta Endocrinol (Copenh) on November 01, 1980
Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains under-recognized and under-diagnosed. Clin Endocrinol (Oxf) (2009) 1.11
Determination of the proliferation and apoptotic index in adrenocorticotropin-secreting pituitary tumors : comparison between micro- and macroadenomas. Am J Pathol (2000) 0.87
Medical therapy of acromegaly. Int J Endocrinol (2012) 0.82
Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst (1998) 6.06
Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients. Br J Cancer (1999) 5.47
Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res (2000) 4.66
Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med (2001) 4.13
BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat Genet (1997) 3.68
Rapid detection of BRCA1 mutations by the protein truncation test. Nat Genet (1995) 3.61
Serum anti-Müllerian hormone levels: a novel measure of ovarian reserve. Hum Reprod (2002) 3.59
Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet (1998) 3.28
Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. Lancet (2000) 2.84
[Cushing's syndrome. I. New diagnostic developments]. Ned Tijdschr Geneeskd (2006) 2.73
Bone density in non-insulin-dependent diabetes mellitus. The Rotterdam Study. Ann Intern Med (1995) 2.70
A polymorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity to glucocorticoids in vivo. J Clin Endocrinol Metab (1998) 2.45
Control of primordial follicle recruitment by anti-Müllerian hormone in the mouse ovary. Endocrinology (1999) 2.42
Measures of bioavailable serum testosterone and estradiol and their relationships with muscle strength, bone density, and body composition in elderly men. J Clin Endocrinol Metab (2000) 2.36
Anti-Müllerian hormone attenuates the effects of FSH on follicle development in the mouse ovary. Endocrinology (2001) 2.28
Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J Clin Oncol (2001) 2.25
Perimesencephalic hemorrhage: a nonaneurysmal and benign form of subarachnoid hemorrhage. Neurology (1985) 2.18
The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res (2000) 2.09
The time course of aneurysmal haemorrhage on computed tomograms. Neuroradiology (1982) 2.06
Anti-mullerian hormone predicts menopause: a long-term follow-up study in normoovulatory women. J Clin Endocrinol Metab (2011) 2.02
Survival in hereditary breast cancer associated with germline mutations of BRCA2. J Clin Oncol (1999) 1.99
Mutant E-cadherin breast cancer cells do not display constitutive Wnt signaling. Cancer Res (2001) 1.78
Somatostatin receptors in human endocrine tumors. Cancer Res (1987) 1.77
Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet (1989) 1.76
A polymorphism in the gene for IGF-I: functional properties and risk for type 2 diabetes and myocardial infarction. Diabetes (2001) 1.76
Cortisol receptor resistance: the variability of its clinical presentation and response to treatment. J Clin Endocrinol Metab (1992) 1.72
Association of radiographically evident osteoarthritis with higher bone mineral density and increased bone loss with age. The Rotterdam Study. Arthritis Rheum (1996) 1.72
High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res (2001) 1.70
Lack of association between five polymorphisms in the human glucocorticoid receptor gene and glucocorticoid resistance. Hum Genet (1997) 1.66
Adrenal glands of mouse and rat do not synthesize androgens. Life Sci (1992) 1.64
Somatostatin-receptor scintigraphy in primary breast cancer. Lancet (1994) 1.63
Prognostic value of p53, bcl-2, and c-erbB-2 protein expression in phaeochromocytomas. J Pathol (1999) 1.62
Relationship of serum antimüllerian hormone concentration to age at menopause. J Clin Endocrinol Metab (2008) 1.60
c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer. Cancer Res (1992) 1.59
Bcar1/p130Cas protein and primary breast cancer: prognosis and response to tamoxifen treatment. J Natl Cancer Inst (2000) 1.54
Internalization of the radioiodinated somatostatin analog [125I-Tyr3]octreotide by mouse and human pituitary tumor cells: increase by unlabeled octreotide. Endocrinology (1995) 1.54
A large-scale population-based study of the association of vitamin D receptor gene polymorphisms with bone mineral density. J Bone Miner Res (1996) 1.54
Circulating IGF-I and its protective role in the pathogenesis of diabetic angiopathy. Clin Endocrinol (Oxf) (2000) 1.53
Vertebral deformities and functional impairment in men and women. J Bone Miner Res (1997) 1.53
Evaluation of a radiolabeled somatostatin analog (I-123 octreotide) in the detection and localization of carcinoid and islet cell tumors. Radiology (1993) 1.52
Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. J Clin Oncol (2000) 1.51
Gender-specific relationship between serum free and total IGF-I and bone mineral density in elderly men and women. Eur J Endocrinol (1998) 1.51
[(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in begnign and malignant pheochromocytomas. J Clin Endocrinol Metab (2001) 1.50
Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols. Cancer Res (1989) 1.48
The endocrine and follicular growth dynamics throughout the menstrual cycle in women with consistently or variably elevated early follicular phase FSH compared with controls. Hum Reprod (2008) 1.46
Insulin-like growth factor-I and risk of breast cancer. Lancet (1998) 1.45
Free and total insulin-like growth factor I (IGF-I), IGF-binding protein-1 (IGFBP-1), and IGFBP-3 and their relationships to the presence of diabetic retinopathy and glomerular hyperfiltration in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab (1997) 1.45
Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res (1992) 1.44
[Good results in periodic screening in women with increased risk of breast cancer; retrospective study]. Ned Tijdschr Geneeskd (1995) 1.44
Haemodynamic and neurohumoral effects of xenon anaesthesia. A comparison with nitrous oxide. Anaesthesia (1990) 1.44
Prediction of relapse and survival in breast cancer patients by pS2 protein status. Cancer Res (1990) 1.43
Relationship between ovarian production of estrone, estradiol, testosterone, and androstenedione and the ovarian degree of stromal hyperplasia in postmenopausal women. Menopause (1998) 1.43
ATM-heterozygous germline mutations contribute to breast cancer-susceptibility. Am J Hum Genet (2000) 1.42
The MTT tetrazolium salt assay scrutinized: how to use this assay reliably to measure metabolic activity of cell cultures in vitro for the assessment of growth characteristics, IC50-values and cell survival. Eur J Clin Chem Clin Biochem (1995) 1.42
Single and repeated GnRH agonist stimulation tests compared with basal markers of ovarian reserve in the prediction of outcome in IVF. J Assist Reprod Genet (2005) 1.42
The association between age and bone mineral density in men and women aged 55 years and over: the Rotterdam Study. Bone Miner (1994) 1.41
Postoperative metyrapone test in the early assessment of outcome of pituitary surgery for Cushing's disease. Clin Endocrinol (Oxf) (1997) 1.41
'Pseudo-aldosteronism' induced by intravenous glycyrrhizin treatment of chronic hepatitis C patients. J Gastroenterol Hepatol (2001) 1.41
Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995. N Engl J Med (1985) 1.41
In vivo use of a radioiodinated somatostatin analogue: dynamics, metabolism, and binding to somatostatin receptor-positive tumors in man. J Nucl Med (1991) 1.41
[Clinically non-functioning hypophyseal adenomas; diagnostic possibilities and therapeutic options]. Ned Tijdschr Geneeskd (1992) 1.40
Etomidate suppresses adrenocortical function by inhibition of 11 beta-hydroxylation. J Clin Endocrinol Metab (1984) 1.39
The relationship between growth hormone (GH) messenger ribonucleic acid levels and hormone release from individual cells derived from human GH-secreting pituitary adenomas. Clin Endocrinol (Oxf) (1991) 1.39
Insulin and cognitive function in an elderly population. The Rotterdam Study. Diabetes Care (1997) 1.39
Corticosteroid therapy in severe illness. N Engl J Med (1997) 1.38
[Chemotherapy in metastasized breast carcinoma]. Ned Tijdschr Geneeskd (1998) 1.38
[A patient with hypocalcemia: an experiment of nature and culture]. Ned Tijdschr Geneeskd (1993) 1.38
Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab (1997) 1.38
Serum total IGF-I, free IGF-I, and IGFB-1 levels in an elderly population: relation to cardiovascular risk factors and disease. Arterioscler Thromb Vasc Biol (1998) 1.37
[Prolactinoma; diagnosis and treatment]. Ned Tijdschr Geneeskd (1996) 1.37
Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol (1994) 1.36
Hormone-producing gastrointestinal tumors contain a high density of somatostatin receptors. J Clin Endocrinol Metab (1987) 1.35
Serum anti-müllerian hormone levels in healthy females: a nomogram ranging from infancy to adulthood. J Clin Endocrinol Metab (2012) 1.35
Retinopathy, glucose, and insulin in an elderly population. The Rotterdam Study. Diabetes (1995) 1.34
The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters. Eur J Cancer (1996) 1.34
Prediction of osteoporotic fractures in the general population by a fracture risk score. A 9-year follow-up among middle-aged women. Am J Epidemiol (1990) 1.34
Interperson variability but intraperson stability of baseline plasma cortisol concentrations, and its relation to feedback sensitivity of the hypothalamo-pituitary-adrenal axis to a low dose of dexamethasone in elderly individuals. J Clin Endocrinol Metab (1998) 1.33
Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. Cancer Res (1989) 1.32
Altered hypothalamus-pituitary-adrenal gland axis regulation in the expanded CGG-repeat mouse model for fragile X-associated tremor/ataxia syndrome. Psychoneuroendocrinology (2008) 1.31
Consequences of vitamin D receptor gene polymorphisms for growth inhibition of cultured human peripheral blood mononuclear cells by 1, 25-dihydroxyvitamin D3. Clin Endocrinol (Oxf) (2000) 1.30
Distribution of somatostatin receptors in normal and tumor tissue. Metabolism (1990) 1.30
Absence of somatostatin receptors in human exocrine pancreatic adenocarcinomas. Gastroenterology (1988) 1.27
A consensus on the diagnosis and treatment of acromegaly complications. Pituitary (2013) 1.26
Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: correlation with steroid receptors. Eur J Cancer (1992) 1.26
Familial glucocorticoid resistance caused by a splice site deletion in the human glucocorticoid receptor gene. J Clin Endocrinol Metab (1993) 1.26
Somatostatin analogue scintigraphy in carcinoid tumours. Eur J Nucl Med (1993) 1.24
Computerized tomography in subarachnoid hemorrhage: difference between patients with and without an aneurysm on angiography. Neurology (1980) 1.23
Advanced breast cancer and its prevention by screening. Br J Cancer (1992) 1.23
Evaluation of a radioimmunoassay for testosterone estimation. J Steroid Biochem (1973) 1.23
Anti-Müllerian hormone: a marker for oocyte quantity, oocyte quality and embryo quality? Reprod Biomed Online (2008) 1.21
Treatment with a luteinising-hormone-releasing-hormone analogue (buserelin) in premenopausal patients with metastatic breast cancer. Lancet (1982) 1.20